Table 2.
List of RSA drugs in South Korea
| Brand name | Active substance | Type | Start date (End date) | Note | |
|---|---|---|---|---|---|
| Activation ongoing | |||||
| Erbitux | cetuximab | refund | 5-Mar-2014 | re-evaluation for RSA (1-Jul-2018) | |
| Xtandi | enzalutamide | refund | 1-Nov-2014 | re-evaluation for RSA (13-Feb-2019) | |
| Soliris | eculizumab | refund | 1-Oct-2015 |
refund pilot program (1-Oct-2012), Essential drug |
|
| Caprelsa | vandetanib | expenditure cap | 1-Nov-2015 | Under EEE | |
| Naglazyme | galsulfase | refund | 1-Mar-2016 |
refund pilot program (1-Oct-2012), Essential drug |
|
| Stivarga | regorafenib | refund | 1-Jun-2016 | ||
| Vimizim | elosulfase alfa | expenditure cap | 1-Jun-2016 | Under EEE | |
| Pomalyst | pomalidomide | refund | 1-Jan-2017 | ||
| Defitelio | defibrotide | expenditure cap | 1-Jun-2017 | Under EEE | |
| Perjeta | pertuzumab |
time cap per patient |
1-Jun-2017 | ||
| Zelboraf | vemurafenib | expenditure cap | 1-Jul-2017 | Under EEE | |
| Kadcyla | trastuzumab emtansine | utilization cap | 3-Aug-2017 | ||
| Opdivo | nivolumab |
refund + expenditure cap |
21-Aug-2017 | ||
| Keytruda | pembrolizumab |
refund + expenditure cap |
21-Aug-2017 | ||
| Rafinlar | dabrafenib | expenditure cap | 1-Sep-2017 | Under EEE | |
| Lynparza | olaparib | expenditure cap | 1-Oct-2017 | Under EEE | |
| Meqsel | trametinib | expenditure cap | 1-Nov-2017 | Under EEE | |
| Ibrance | palbociclib | refund | 6-Nov-2017 | ||
| Tagrisso | osimertinib |
discounted treatment initiation |
5-Dec-2017 | ||
| Tecentriq | atezolizumab | expenditure cap | 12-Jan-2018 | Under EEE | |
| Sylvant | siltuximab | expenditure cap | 1-Feb-2018 | Under EEE | |
| Kyprolis | carfilzomib | refund | 5-Feb-2018 | ||
| Iclusig | ponatinib | expenditure cap | 1-Apr-2018 | Under EEE | |
| Imbruvica | ibrutinib | expenditure cap | 1-Apr-2018 | Under EEE | |
| Cyramza | ramucirumab | refund | 1-May-2018 | ||
| Blincyto | blinatumomab | expenditure cap | 1-Jul-2018 | Under EEE | |
| Vyndaqel | tafamidis | expenditure cap | 1-Oct-2018 | Under EEE | |
| Cabometyx | cabozantinib |
refund + expenditure cap |
1-Feb-2019 | ||
| Praxbind | idarucizumab | expenditure cap | 1-Feb-2019 | Under EEE | |
| Darzalex | daratumumab |
refund + expenditure cap |
8-Apr-2019 | ||
| Spinraza | nusinersen |
refund + expenditure cap |
8-Apr-2019 | ||
| Limited activation | |||||
| Olita | olmutinib | expenditure cap | 15-Nov-2017 | Under EEE | |
| Lartruvo | olaratumab | expenditure cap | 1-Dec-2018 | Under EEE | |
| Expired activation | |||||
| Evoltra | clofarabine | CED |
11-Dec-2013 (1-Dec-2018) |
the first RSA drug, conventional reimbursement after re-evaluation |
|
| Revlimid | lenalidomide | refund |
5-Mar-2014 (1-Dec-2017) |
conventional reimbursement due to generic | |
| Xalkori | crizotinib | refund |
1-May-2015 (1-May-2019) |
conventional reimbursement due to alternative drugs after re-evaluation | |
| Pirespa | pirfenidone | refund |
3-Oct-2015 (1-Nov-2017) |
conventional reimbursement due to generic | |
| Diterin | sapropterin | expenditure cap |
1-Nov-2017 (8-May-2019) |
Under EEE, conventional reimbursement due to generic |
|
| Alecensa |
alectinib hydrochloride |
expenditure cap |
1-Oct-2017 (1-Dec-2018) |
Under EEE, conventional reimbursement due to alternative drugs after expansion of the indication |
|
RSA risk sharing arrangement, EEE exemption of economic evaluation, CED coverage with evidence development